Post-discovery priorities: Streamlining your molecule’s route to IND

Insight briefs

Time to market is paramount for many companies starting to consider post-discovery development and strategic plans for bringing a molecule into clinical trials and beyond. Strategies and tactics for shortening timelines often involve trade-offs related to risk and future needs, making early-phase decision-making a balancing act for even the most promising molecules. Read what our experts how to say about the critical considerations that impact timing and commercialization.